Uveitis, an inflammatory condition affecting the uveal tract of the eye, remains a leading cause of preventable blindness worldwide. For decades, corticosteroids have been the cornerstone of treatment, but their long-term use is associated with significant side effects, including cataracts and glaucoma. The emergence of biologic therapies is transforming the treatment landscape, offering targeted alternatives that address the underlying immune mechanisms driving the disease.

The Uveitis Drug Market was valued at approximately USD 3.62 billion in 2024 and is projected to reach USD 6.21 billion by 2035, growing at a CAGR of 5.01%. Biologics, particularly anti-TNF agents like AbbVie's HUMIRA, are increasingly prescribed as steroid-sparing alternatives for chronic, non-infectious uveitis. HUMIRA became the first FDA-approved non-corticosteroid therapy for adults with non-infectious intermediate, posterior, and panuveitis, marking a significant milestone in the field. These targeted therapies offer improved long-term safety profiles and reduced recurrence rates compared to sustained corticosteroid use.

The market is also benefiting from a robust pipeline of novel biologics and small-molecule immunomodulators. Pharmaceutical companies are investing heavily in research and development, supported by expedited regulatory pathways. The EMA recommended 114 medicines for marketing authorization in 2024, including 46 with new active substances, reflecting a favorable environment for innovation. As personalized medicine continues to advance, the Uveitis Drug Market is poised for sustained growth, with biologics leading the way.

People Also Ask

• What drugs are used to treat uveitis?
  Uveitis is treated with corticosteroids, immunosuppressive drugs, biologics (such as anti-TNF agents), and NSAIDs. Biologics are increasingly used for chronic, non-infectious cases.

• Are biologics better than steroids for uveitis?
  Biologics offer targeted treatment with fewer long-term side effects compared to sustained corticosteroid use, making them preferable for chronic cases.

Tags: #UveitisDrug #Biologics #EyeCare #Ophthalmology #HUMIRA #AntiTNF